Full text is available at the source.
Abstract
A non-metallic MRI contrast agent named TARGET may enhance glioma diagnostic accuracy.
- TARGET is composed of a serotonin-derived lipid nanoparticle and an engineered mRNA for glioma-specific expression.
- The mRNA encodes aquaporin-1, which creates a water channel on cell membranes to improve MRI contrast.
- The design of the 3'UTR allows the mRNA to degrade in healthy tissues, facilitating the detection of pseudoprogression.
- TARGET may serve as an effective alternative to gadolinium-based contrast agents in brain tumor diagnosis.
- This proof-of-concept study suggests that TARGET could improve the differentiation between true tumor progression and pseudoprogression.
Simplified
mRNA Technology